One interesting finding from comparison studies shows Retatrutide might reduce visceral fat (the dangerous fat around organs) better than Tirzepatide
Researchers have documented this distinction across the published mechanism literature
Their approval for weight management spans markets in Europe, Asia-Pacific, and India, where increasing obesity rates have driven demand
Dysbiosis impairs the intestinal barrier, increasing its permeability and allowing bacteria and lipopolysaccharides (LPS) from the gut to translocate into the systemic circulation, leading to systemic inflammation (148)
If it is semaglutide-specific, switching to tirzepatide might resolve the issue
The Harmony Outcomes trial further revealed that albiglutide reduced MACE by 22% over a median follow-up period of 1.6 years in patients with type 2 diabetes and cardiovascular disease ( p = 0.0006) [70]